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Silencing of the integrated human immunodeficiency virus type 1 (HIV-1) genome in resting CD4 T cells
is a significant contributor to the persistence of infection, allowing the virus to evade both immune detection
and pharmaceutical attack. Nonselective histone deacetylase (HDAC) inhibitors are capable of inducing
expression of quiescent HIV-1 in latently infected cells. However, potent global HDAC inhibition can induce
host toxicity. To determine the specific HDACs that regulate HIV-1 transcription, we evaluated HDAC1 to
HDAC11 RNA expression and protein expression and compartmentalization in the resting CD4 T cells of
HIV-1-positive, aviremic patients. HDAC1, -3, and -7 had the highest mRNA expression levels in these cells.
Although all HDACs were detected in resting CD4 T cells by Western blot analysis, HDAC5, -8, and -11 were
primarily sequestered in the cytoplasm. Using chromatin immunoprecipitation assays, we detected HDAC1, -2,
and -3 at the HIV-1 promoter in Jurkat J89GFP cells. Targeted inhibition of HDACs by small interfering RNA
demonstrated that HDAC2 and HDAC3 contribute to repression of HIV-1 long terminal repeat expression in
the HeLa P4/R5 cell line model of latency. Together, these results suggest that HDAC inhibitors specific for a
limited number of class I HDACs may offer a targeted approach to the disruption of persistent HIV-1 infection.
Persistent proviral human immunodeficiency virus type 1
(HIV-1) infection, primarily within a small population of long-
lived resting CD4 T cells, is a central obstacle to the clearance
of established HIV-1 infection. This is due, in part, to the
occasional silencing of proviral HIV-1 genomes in resting
CD4 T cells, shielding this reservoir from immunological or
pharmaceutical attack. To overcome proviral latency, potent
and clinically tolerable agents capable of inducing expression
of latent HIV-1 must be identified. Such efforts will be aided by
an understanding of mechanisms that regulate transcription
from the HIV-1 5 long terminal repeat (LTR) promoter.
Once integrated, HIV-1 resides in the host chromatin envi-
ronment, where its genome is packaged around histone octam-
ers (25). The N-terminal tails of histones can be chemically
modified by multiple enzymes including histone acetyltrans-
ferases and histone deacetylases (HDACs) (reviewed in refer-
ence 5). Acetylation of the lysine residues in histone tails by
histone acetyltransferases allows transcriptional machinery ac-
cess to the DNA template and serves as a signal for recruit-
ment of transcription factors and complexes that upregulate
gene expression. Conversely, HDACs are a family of lysine
deacetylases that act on multiple targets, including histone
tails. Deacetylation of histones creates a chromatin environ-
ment unfavorable to transcription, in part by creating a plat-
form for the recruitment of histone methyltransferases and
other factors that repress transcription. There are 18 known
human HDACs, which are divided into four classes based on
amino acid sequence and domain organization (reviewed in
reference 5). Class I HDACs (HDAC1, -2, -3, and -8); class II
HDACs (HDAC4, -5, -6, -7, -9, and -10); and the class IV
HDAC, HDAC11, are all sensitive to global HDAC inhibitors
such as trichostatin A (TSA). Class III HDACs, also known as
the sirtuins, are structurally unrelated to the other classes and
are not sensitive to traditional HDAC inhibitors.
Evidence suggests that mechanisms of acetylation and
deacetylation regulate HIV-1 proviral expression (reviewed in
reference 22). HDACs are recruited to the initiator and en-
hancer regions of the HIV-1 promoter by several transcription
factors and corepressor complexes. The recruitment of
HDAC1 to the latent HIV-1 LTR was first shown to be me-
diated by YY1 and LSF (4), and later studies demonstrated
that NF-B p50 homodimers (26), AP-4 (10), CTIP2 (20), Sp1
and c-Myc (12), and CBF-1 (23) could all participate in
HDAC1 recruitment. CTIP2 was also found to recruit HDAC2
to the Sp1 binding site of the LTR in microglial cells (20).
Furthermore, HDAC3 has been shown to associate with the
HIV-1 LTR (18). HDAC3 occupancy at the LTR is further
supported by evidence demonstrating recruitment of the
HDAC3-containing corepressor complexes, N-CoR and SMRT,
by unliganded thyroid hormone receptor in a Xenopus laevis
oocyte model system for chromatin assembly (9).
The existence of multiple mechanisms that recruit HDACs
to the proviral promoter may be of high therapeutic signifi-
cance. Nonselective HDAC inhibition with potent agents such
as TSA can induce HIV-1 expression in cell line models of
latency (15, 16, 24). Furthermore, HDAC inhibitors induce
viral expression in resting CD4 T cells obtained from avire-
mic, HIV-1-positive patients (1, 27). Inhibitors specific for the
individual HDACs relevant to HIV-1 LTR regulation may
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provide a more selective targeting of the viral promoter and
avoid toxicities that can accompany robust, global HDAC in-
hibition.
To define the specific HDACs that regulate HIV-1 tran-
scription during latency, we characterized mRNA expression
and protein expression and localization of HDAC1 to -11 in
the resting CD4 T cells of HIV-1-positive patients. We eval-
uated HDAC occupancy at the HIV-1 LTR and the effect of
targeted HDAC inhibition on HIV-1 transcriptional activation
in cell line models of HIV-1 latency. We find that HDAC2 and
HDAC3 play a prominent role in the regulation of HIV-1
expression. These enzymes may be important targets for selec-
tive antilatency therapies.
MATERIALS AND METHODS
Primary CD4 T cells and cell lines. Resting CD4 T cells were obtained from
aviremic (50 HIV-1 RNA copies/ml plasma), HIV-1-positive patients on stable
antiretroviral therapy with CD4 T-cell counts of 300/l via continuous-flow
leukapheresis. Peripheral blood mononuclear cells were purified from leuka-
pheresis products using a Ficoll gradient and subjected to a negative-selection
purification using an antibody cocktail of anti-CD8, anti-CD14, anti-CD16, anti-
CD19, anti-CD56, anti-glycophorin A, anti-CD41, anti-CD25, and anti-HLA-DR
as previously described (2) to obtain purified (97%) resting CD4 T cells
defined as a CD4 CD45 CD3 CD69 CD25 CD8 CD14 HLA-DR
population by fluorescence-activated cell sorting analysis. J89GFP cells (16) were
maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin (Invitrogen), and 100 g/ml streptomycin
(Invitrogen). HeLa P4/R5 cells (14) were cultured in phenol red-free Dulbecco
modified Eagle medium (Invitrogen) supplemented with 10% fetal bovine se-
rum, 0.5 mg/ml puromycin (Sigma, St. Louis, MO), 100 U/ml penicillin, and 100
g/ml streptomycin.
RNA extraction and microarray analysis. RNA was extracted from purified
resting CD4 T cells of aviremic, HIV-1-positive patients and hybridized to a
microarray of 23,500 60-mer oligonucleotides from Agilent Technologies (Palo
Alto, CA) as previously described (12). Intensities of HDAC mRNA expression
were normalized to an Agilent internal standard and converted to log ratio values
using the Rosetta Resolver system (Rosetta Biosoftware, Seattle, WA).
Western blot analysis of protein expression and localization. For fractionation
of nuclear and cytoplasmic proteins, purified resting CD4 T or J89GFP cells
were first lysed for 10 min on ice in a buffer containing 10 mM HEPES, pH 7.5,
5 mM KCl, 1.5 mM MgCl2, 0.1% NP-40, 10 mM NaF, and protease inhibitor
cocktail (Sigma). Following centrifugation, cytoplasmic extracts were removed
and nuclei were incubated in RIPA buffer with protease inhibitor cocktail
(Sigma) and 10 mM NaF for 10 min on ice. Cellular debris was removed by
centrifugation, and nuclear extracts were collected. Protein concentrations were
determined using Bradford protein assays (Bio-Rad). To denature proteins,
extracts were heated at 95°C for 5 min in NuPAGE LDS sample buffer and
NuPAGE sample reducing agent (Invitrogen). Protein extracts were separated
on 4 to 12% Bis-Tris sodium dodecyl sulfate-polyacrylamide gels (Invitrogen)
and transferred to polyvinylidene difluoride membranes (Bio-Rad). Membranes
were probed with the following antibodies: anti-HDAC1 (sc-7872x), anti-
HDAC2 (sc-7899x), anti-HDAC3 (sc-11417x), anti-HDAC6 (sc-11420), anti-
HDAC7 (sc-11421x), anti-HDAC8 (sc-11405), and anti-HDAC9 (sc-28732)
(Santa Cruz Biotechnology, Santa Cruz, CA); anti-HDAC4 (40969) and anti-
HDAC5 (40970) (Active Motif, Carlsbad, CA); anti-HDAC10 (AP1110a) and
anti-HDAC11 (AP1111b) (Abgent, San Diego, CA); anti-lamin B1 (ab16048)
and anti-alpha-tubulin (ab7291) (Abcam, Cambridge, MA); and anti-glyceralde-
hyde-3-phosphate dehydrogenase (MAB374) (Millipore, Billerica, MA). Mem-
branes were then washed and incubated with the corresponding horseradish
peroxidase-conjugated secondary antibodies from ECL-Amersham (GE Health-
care, Piscataway, NJ). Proteins were visualized using ECL or ECL Plus detection
reagent and developed on Hyperfilm ECL (GE Healthcare). Whole-cell protein
extracts from resting CD4 T cells were collected by incubating cells in RIPA
buffer as described above. Membranes were stripped by incubation in 62 mM
Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate, and 2.7% -mercaptoethanol for
25 min at 56°C and reprobed with antibodies as needed.
ChIP assays. J89GFP cells were fixed with 1% formaldehyde for 10 min at
room temperature and subjected to the chromatin immunoprecipitation (ChIP)
procedure using a ChIP assay kit (Millipore) following the manufacturer’s pro-
tocol. Each immunoprecipitation was performed with approximately 1 million
cells and 5 to 10 g of the following ChIP-validated antibodies: anti-HDAC1
(sc-7872x), anti-HDAC2 (sc-7899x), and anti-HDAC3 (sc-11417x) from Santa
Cruz; anti-HDAC4 (40969) or anti-HDAC6 (40971) from Active Motif; or anti-
HDAC7 (ab1441) from Novus Biologicals (Littleton, CO). Rabbit immunoglob-
ulin G (IgG) serum (5 to 24 g; Sigma) was used to control for nonspecific
immunoprecipitation of DNA. After formaldehyde de-cross-linking and protein-
ase K digestion (Roche, Nutley, NJ), DNA was purified using a QIAquick PCR
purification kit (Qiagen, Germantown, MD) in accordance with the manufactur-
er’s protocol.
Immunoprecipitated DNA was amplified using LTR 109F/LTR 82R (27)
or LTR7F/LTR8R (12) primers to detect enrichment of the HIV-1 LTR and
visualized by separating PCR products on an 8% acrylamide gel stained with
ethidium bromide. Images were obtained using an InGenius L gel documenta-
tion system and GeneSnap software (Syngene, Frederick, MD). For quantitative
PCR assays, ChIP DNA was amplified using LTRrt8 (5-TAGCCAGAGAGCT
CCCAGGCTCAGA-3) and LTRrt9 (5-AGCCCTCAGATGCTACATATAA
GCA-3) primers and Power SYBR green PCR Master Mix from Applied Bio-
systems (Foster City, CA). Values represent the enrichment over the IgG
negative control using the threshold cycle (2		CT) method.
siRNA transfection and -galactosidase assays. Three distinct small interfer-
ing RNAs (siRNAs) were designed to each HDAC transcript based on predictors
of on- and off-target activity (Sigma-Proligo). The sense sequences of siRNAs
were as follows: HDAC1-1, CGCCAAGUGUGUGGAAUUU; HDAC1-2, CG
AAUCCGCAUGACUCAUA; HDAC1-3, CUCAUAAUUUGCUGCUCAA;
HDAC2-1, CAAAUACUAUGCUGUCAAU; HDAC2-2, CUCAUUAUCUG
GUGAUAGA; HDAC2-3, CAGUGAUGAGUAUAUCAAA; HDAC3-1, CC
AAGAGUCUUAAUGCCUU; HDAC3-2, GGCACCCAAUGAGUUCUAU;
HDAC3-3, CAUUCAGGAUGGCAUACAA; HDAC8-1, CAUUCAGGAUG
GCAUACAA; HDAC8-2, GACCGUGUCCCUGCACAAA; HDAC8-3, CAG
UAUGGUGCAUUCUUUG. Individual siRNAs were reconstituted in nuclease-
free water to achieve a 20 M solution. The siRNAs targeting a single HDAC
transcript were pooled at a 1:1:1 ratio prior to transfection. The siCONTROL
Non-Silencing 1 (NS1) negative control was purchased from Dharmacon
(Lafayette, CO) and reconstituted according to the manufacturer’s protocol.
All siRNA transfection experiments were performed using HeLa P4/R5 cells.
Briefly, cells were plated in 96-well, white tissue culture-treated plates (Corning,
Corning, NY) in 80 l of assay medium (phenol red-free Dulbecco modified
Eagle medium supplemented with 10% fetal bovine serum, 0.5 mg/ml puromycin
[Sigma], 100 U/ml penicillin, and 100 g/ml streptomycin [Invitrogen]) at 1 
 105
cells/ml and incubated overnight at 37°C and 5% CO2. Prior to transfection,
siRNA-Oligofectamine (Invitrogen) complexes were established according to the
manufacturer’s protocol and then added to each well to achieve a final concen-
tration of 50 nM siRNA and 0.5% Oligofectamine. After incubation at 37°C and
5% CO2 for 20 h, medium was removed from the cells and replaced with assay
medium containing either 1 M TSA or 1% dimethyl sulfoxide (DMSO). Fol-
lowing 20 h of incubation at 37°C and 5% CO2, LTR-mediated -galactosidase
activity was measured using Gal-Screen (Applied Biosystems) according to the
manufacturer’s protocol.
Cell proliferation assays. Cell proliferation was evaluated following transfec-
tion with HDAC siRNA and incubation with TSA or DMSO using the alamar-
Blue assay (Trek Diagnostic Systems, Cleveland, OH) according to the manu-
facturer’s protocol.
Statistical analysis. Normalized -galactosidase activity and cell proliferation
following siRNA-mediated HDAC knockdown were analyzed by the nonpara-
metric Kruskal-Wallis test. To make individual comparisons against the mock
control, the Mann-Whitney U test was applied post hoc with Bonferroni’s cor-
rection. Analyses were performed using SPSS (version 16.0) software (Chicago,
IL). A P value less than 0.05 was considered statistically significant.
RESULTS
HDAC1, -3, and -7 are highly expressed in resting CD4 T
cells. To determine which HDACs are expressed in resting
CD4 T cells, the primary reservoir for latent HIV-1 infection,
we calculated the relative intensities of mRNA expression for
HDAC1 to -11. Levels of HDAC mRNA expression were
similar between patients. HDAC1, -3 and -7 had the highest
mRNA expression levels (Fig. 1A). However, as these levels
were derived from microarray data, they provide information
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on only the relative intensities of HDAC expression in the
resting CD4 T cells of the patients and not absolute expres-
sion levels.
To evaluate HDAC protein expression, we obtained whole-
cell extracts from the resting CD4 T cells of three additional
HIV-1-positive patients and performed Western blot analysis
using antibodies specific for HDAC1 to -11. HDAC1 to -11
were detected in all three patients, and levels of HDAC pro-
tein expression were relatively constant between patients (Fig.
1B). As a positive control, we performed Western blotting on
2 g of lysate from 293T cells transfected with an HDAC10
expression plasmid (lysate obtained by Abgent) to verify the
ability of the HDAC10 antibody to function in Western blot-
ting. Although HDAC10 was undetectable in 20 g of whole-
cell extracts as shown in Fig. 1B, HDAC10 was detected when
Western blot analysis was performed on 40 g of whole-cell
extracts (data not shown). However, the low levels of HDAC10
expression in resting CD4 T cells suggest that it is unlikely to
contribute to HIV-1 latency.
HDAC5, -8, and -11 are predominantly cytoplasmic in rest-
ing CD4 T cells. To determine the localization of HDACs
within resting CD4 T cells, we separated cellular lysates into
nuclear and cytoplasmic fractions and evaluated HDAC pro-
tein expression by Western blot analysis. Most HDACs were
expressed in the nucleus, and many were detectable in both the
nuclear and the cytoplasmic fractions (Fig. 2). However,
HDAC5, -8, and -11 were primarily localized to the cytoplasm.
These findings suggest that it is unlikely that HDAC5, -8, or -11
plays a direct role in regulating transcription driven by the
LTR at the level of chromatin modification in the latent res-
ervoir of resting CD4 T cells, although it is possible that some
amounts of these enzymes reside in the nucleus below the level
of detection of the antibodies used in this assay. Furthermore,
it does not exclude a possible contribution to transcriptional
FIG. 1. HDAC mRNA expression in resting CD4 T cells from aviremic, HIV-1-positive patients. (A) HDAC1, -3, and -7 are the most highly
expressed HDAC mRNAs in resting CD4 T cells. Microarray analysis of mRNA expression in the resting CD4 T cells from three HIV-1-positive
patients provided relative intensities of HDAC mRNA expression. (B) HDAC1 to -11 are detectable in resting CD4 T cells. Whole-cell extracts
were obtained from the resting CD4 T cells of HIV-1-positive patients, and 20 g of protein was subjected to Western blot analysis with
antibodies specific for HDAC1 to -11. An antibody against the nuclear envelope marker lamin B1 was used as a loading control. As a positive
control () for the anti-HDAC10 antibody, 2 g of whole-cell extracts from 293T cells transfected with an HDAC10 expression plasmid was
subjected to Western blotting. Although HDAC10 was not detected in patient extracts in the experiment shown, it was detected when 40 g of
extracts was assayed (data not shown).
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regulation by these HDACs in a pathway upstream of the LTR
through deacetylation of cellular factors in the cytoplasm.
HDAC10 expression levels were too low to permit appropriate
analysis of localization in resting CD4 T cells.
Because latency is a phenomenon that occurs in resting
CD4 T cells and not activated CD4 T cells, we examined
whether there was a differential regulation of HDAC expres-
sion and/or localization in these two cell types. Most HDACs
had similar expression levels and localization before and after
mitogen stimulation with phytohemagglutinin (PHA) (Fig. 2).
However, following T-cell activation, HDAC7 expression dra-
matically increased and became almost exclusively sequestered
in the cytoplasm. Additionally, although HDAC11 remained
cytoplasmic following T-cell activation, there was a noticeable
decrease in HDAC11 protein expression. The differential reg-
ulation in the expression and localization of HDAC7 and
HDAC11 in resting compared to activated CD4 T cells sug-
gests that they may be serving different functions in the two cell
populations. However, siRNA-mediated knockdown of HDAC7
or HDAC11 in the HeLa P4/R5 cell line model of HIV-1
latency did not induce LTR activation (data not shown). Thus,
although HDAC7 and HDAC11 are differentially regulated in
resting versus activated CD4 T cells, we found no evidence
that they contribute to silencing of the proviral HIV-1 LTR.
HDAC1, -2, and -3 are resident at the HIV-1 LTR. Of
HDAC1 to -11, there is evidence that HDAC1, -2, and -3 are
recruited to the LTR in model cell lines of HIV-1 latency (4,
10, 12, 18, 20, 23, 26). Other HDACs could play an important
role in HIV-1 regulation and could be critical for effective
therapeutic targeting of latent infection. The frequency of la-
tent HIV-1 in resting CD4 T cells has been estimated at less
than 1 in 107 cells (3). Because proviral latency is an extremely
rare event, it is impossible to perform ChIP assays on resting
CD4 T cells obtained from patients, due to the small amount
of target DNA. Thus, to address experimentally the question of
which HDACs occupy the HIV-1 LTR, we utilized J89GFP
cells. J89GFP cells are a Jurkat cell line that contains a stably
integrated, full-length HIV-1 provirus (strain 89.6) with a
green fluorescent protein (GFP) reporter incorporated into
the viral genome (16). The viral genome in J89GFP cells is
transcriptionally silent. However, upon appropriate stimula-
tion, such as with the NF-B inducer, tumor necrosis factor
alpha, or the HDAC inhibitor TSA, viral transcription is acti-
vated and viral expression can be measured by GFP production
(27). Critically, this cell line reproducibly returns to quiescence
when stimuli are withdrawn.
First we determined the protein expression and cellular lo-
calization of HDAC1 to -11 in J89GFP cells by Western blot
analysis of 30 g of nuclear and cytoplasmic protein fractions.
Due to the abundance of cell line extract, we were able to use
twice as much protein in these Western blot assays as in those
performed with scarce material extracted from available avire-
mic, HIV-infected patients’ cells. We were able to detect all 11
HDACs in J89GFP cells (Fig. 3A). The nuclear and cytoplas-
mic distribution of HDACs in J89GFP cells mirrors that of
resting CD4 T cells with the exception that HDAC1 and
HDAC8 are detected in both the nucleus and the cytoplasm of
J89GFP cells. Although these slight differences in HDAC ex-
pression between the J89GFP cells and resting CD4 T cells
may be relevant to HIV-1 latency, importantly, all HDACs that
are expressed in the nuclei of resting CD4 T cells are also
present in the nuclei of J89GFP cells. Thus, J89GFP cells are
a reasonable model cell line to evaluate HDAC recruitment to
the integrated HIV-1 LTR by ChIP.
To assess the occupancy of the various HDACs at the HIV-1
LTR, we first performed ChIP assays using antibodies directed
FIG. 2. HDAC5, -8, and -11 are excluded from the nuclei of resting CD4 T cells. Resting CD4 T cells from an aviremic, HIV-1-positive
patient (patient 5 from Fig. 1A) were maintained in medium (Rest) or activated by incubation with 1 g/ml of the mitogen PHA overnight (Act)
before cellular lysates were harvested. Proteins were separated into nuclear (N) and cytoplasmic (C) fractions, and 15 g of extracts was probed
with antibodies targeting HDAC1 to -11 in Western blot analysis. Antibodies against lamin B1 and glyceraldehyde-3-phosphate dehydrogenase
were used to assess loading of nuclear and cytoplasmic lysates. HDAC5, -8, and -11 were primarily localized to the cytoplasm in CD4 T cells.
Following T-cell activation with PHA, HDAC7 expression increased and became sequestered in the cytoplasm, while HDAC11 expression
decreased.
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against the class I HDACs that were detected in the nuclear
protein extracts of resting CD4 T cells: HDAC1, -2, and -3.
We observed HDAC1, -2, and -3 at the HIV-1 LTR (Fig. 3B)
of J89GFP cells. These results agree with previous findings in
diverse cell systems that HDAC1, -2, and -3 are recruited to
the HIV-1 LTR (4, 10, 12, 18, 20, 23, 26). However, to our
knowledge this is the first report of HDAC2 occupying the
LTR in a T-lymphocytic cell line. Although the amount of
HIV-1 LTR DNA immunoprecipitated with an HDAC3 anti-
body was smaller than the amount immunoprecipitated with
HDAC1 or HDAC2 antibodies, it was a consistent finding
observed over multiple experiments. Such results do not nec-
essarily indicate that there are fewer HDAC3 molecules asso-
ciated with the HIV-1 LTR, as they may simply reflect the
ability of the particular antibody to perform in ChIP assays, the
distance of the target enzyme from the DNA, or the availability
of corresponding epitopes following formaldehyde fixation.
Next we examined the HIV-1 LTR occupancy levels of the
predominant, nuclear class II HDACs in resting CD4 T cells,
HDAC4, -6, and -7. We did not detect significant levels of
HIV-1 LTR DNA enrichment over the IgG negative control
following ChIP with ChIP-validated antibodies targeting
FIG. 3. HDAC1, -2, and -3 are recruited to the HIV-1 LTR in the J89GFP cell line model of latency. (A) HDAC localization in J89GFP cells
is similar to that in resting CD4 T cells. Nuclear (N) and cytoplasmic (C) protein extracts (30 g each) from J89GFP cells were probed with
antibodies against HDAC1 to -11 in Western blot analysis. Antibodies targeting lamin B1 and alpha-tubulin were used as loading controls for
nuclear and cytoplasmic extracts, respectively. (B) HDAC1, -2, and -3 associate with the HIV-1 LTR. Antibodies targeting the nuclear class I
HDACs HDAC1, -2, and -3 were used in ChIP assays in J89GFP cells. Rabbit IgG serum was used to assay nonspecific immunoprecipitation of
LTR DNA. (C) The nuclear class II HDACs HDAC4, -6, and -7 do not associate with the HIV-1 LTR. ChIP assays were performed in J89GFP
cells. HDAC2 was used as a positive control, and rabbit IgG serum was used as a negative control. Values in panels B and C represent the
enrichment of LTR DNA over the IgG negative control as determined by quantitative PCR. Experiments were performed on at least three
occasions. Data are expressed as the means  standard errors of the means.
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HDAC4, -6, or -7 (Fig. 3C). In these experiments, HDAC2 was
used as a positive control to verify the success of the ChIP
assay. However, as we are unaware of a positive-control region
of DNA in J89GFP cells to verify the ability of these antibodies
to work in ChIP assays in our hands, we cannot completely
exclude the possibility that some levels of these enzymes may
associate with the LTR. Taken together, these findings suggest
that the class I HDACs HDAC1, -2, and -3 are the predomi-
nant HDACs to occupy the HIV-1 LTR in the J89GFP model
of latency.
HDAC2 and HDAC3 regulate LTR-driven gene expression.
To determine the impact of individual HDACs on the regula-
tion of HIV-1 transcription, we treated the HIV-1 latency cell
line model, HeLa P4/R5 cells (14), with siRNAs targeting the
class I HDACs, HDAC1, -2, -3, and -8. HeLa P4/R5 cells are
a variant of HeLa Magi cells that express both CXCR4 and
CCR5. They contain an integrated lacZ gene under the control
of the HIV-1 minimal LTR and were selected for low back-
ground -galactosidase expression. As these cells contain only
an integrated LTR promoter driving a LacZ reporter, they
permit identification of factors that exert strong regulation
over transcription from the LTR in the absence of Tat.
Silencing of HDAC2 mRNA led to a statistically significant
increase in LacZ production as measured by -galactosidase
assays (Fig. 4A). Isolated knockdown of HDAC1, -3, and -8 did
not result in a significant increase in LTR-driven LacZ expres-
sion. Using the alamarBlue assay, we evaluated cell prolifera-
tion following siRNA-mediated knockdown of HDAC1, -2, -3,
and -8 and observed no differences in cell viability compared to
the mock control (Fig. 4C). Thus, the lack of LTR induction
seen with siRNA-mediated silencing of HDAC1, -3, and -8 is
not due to a decrease in the viability or proliferation of cells
following HDAC knockdown.
When proteins like HDAC3 are expressed at high levels in
cells, it can be difficult to achieve a full knockdown of expres-
sion using siRNA alone. We observed substantial reductions
(93%) of HDAC mRNA expression following siRNA knock-
down as determined by reverse transcriptase PCR (data not
shown). However, to overcome the effect of residual HDAC
protein that may persist despite HDAC mRNA knockdown,
we combined chemical HDAC inhibition with siRNA-medi-
ated knockdown. Based on the 50% to 90% effective concen-
tration for TSA induction of the LTR in HeLa P4/R5 cells, we
treated P4/R5 cells with a submaximal concentration of TSA in
conjunction with individual siRNA-mediated knockdowns of
the class I HDACs. Combining TSA with individual siRNAs
against HDAC1, -2, or -8 did not lead to a significant increase
in LTR activation above that induced by TSA alone (Fig. 4B).
Activation of the LTR by HDAC2 siRNA was not observed in
this experiment because mock transfection combined with
TSA treatment induced higher levels of -galactosidase activ-
ity (18-fold) than did isolated HDAC2 knockdown; thus, the
FIG. 4. HDAC2 and HDAC3 negatively regulate the HIV-1 LTR. (A) siRNA-mediated knockdown of HDAC2 induced a significant increase
in LTR-driven lacZ expression compared to the mock control (n  64; ***, P  0.001). P4/R5 cells were transfected with siRNAs targeting the
class I HDACs HDAC1, -2, -3, and -8. Twenty hours posttransfection, cells were incubated with 1% DMSO (vehicle control) for an additional 20 h.
As a control, cells were transfected with nonspecific (NS) siRNA. Values are displayed in relative light units and were derived from Gal-Screen
assays of cellular lysates. (B) siRNA knockdown of HDAC3 in conjunction with exposure to a submaximal concentration of the HDAC inhibitor
TSA upregulated LTR-driven lacZ expression compared to cells that were mock transfected and exposed to TSA (n  32; ***, P  0.001). Cells
were treated as for panel A except that 1 M TSA was added in place of DMSO. (C) There were no differences in cell proliferation following
HDAC knockdown compared to the mock controls (n  12, P  0.522 for DMSO experiment; n  12, P  0.307 for TSA experiment). alamarBlue
assays were used to assess cell viability in panels A and B. Data in panels A to C are the combined results of at least three experiments and are
expressed as the means  standard errors of the means.
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backgrounds of the two experiments are different. Exposure to
global HDAC enzymatic inhibition along with a targeted
knockdown of HDAC3, however, led to a significant increase
in LTR activation over that in the mock-transfected cells that
were treated with TSA alone (Fig. 4B). There were no differ-
ences in cell proliferation following TSA treatment with tar-
geted HDAC knockdowns compared to the mock control (Fig.
4C). Taken together, these findings suggest that both HDAC2
and HDAC3 contribute to the restriction of HIV-1 LTR ex-
pression in HeLa P4/R5 cells.
DISCUSSION
In this study, we provide the first comprehensive assessment
of the contribution of HDAC1 to -11 to HIV-1 latency in
resting CD4 T cells. Our results suggest that the class I
HDACs HDAC1, -2, and -3 are recruited to the HIV-1 LTR
and that HDAC2 and HDAC3 regulate HIV-1 transcriptional
repression in cell line models of HIV-1 latency. HDAC1, -2,
and -3 are expressed in the nuclei of resting CD4 T cells (Fig.
1A and B and 2); thus, their contribution to HIV-1 transcrip-
tional repression may extend to a clinically relevant viral res-
ervoir.
Our data suggest that HDAC2 may be particularly impor-
tant to the regulation of HIV-1 expression. Because ChIP is
not feasible in resting CD4 T cells from HIV-1-positive pa-
tients due to the rarity of target DNA, we performed ChIP
assays in the J89GFP cell line model of HIV-1 latency. We
observed HDAC2 associating with HIV-1 LTR DNA. Al-
though HDAC2 was previously reported to be recruited to the
LTR in microglial cells (20), to our knowledge this is the first
report of HDAC2 being detected at the HIV-1 LTR in a
T-lymphocytic cell line (Fig. 3B). Isolated knockdown of
HDAC2 by siRNA resulted in a significant increase in LTR-
driven gene expression (Fig. 4A) in HeLa P4/R5 cells. These
results are similar to those of Marban et al. (20), who detected a
modest 1.5-fold increase in LTR-driven expression of a luciferase
reporter when HDAC2 was targeted by short hairpin RNA.
As previously reported (18), we found that HDAC3 was
recruited to the HIV-1 LTR (Fig. 3B). Additionally, in com-
bination with global HDAC enzymatic inhibition by TSA,
siRNA-mediated knockdown of HDAC3 resulted in a synergistic
increase in HIV-1 expression (Fig. 4B). We achieved a substantial
knockdown of HDAC3 mRNA (93%; data not shown), but LTR
upregulation was seen only when the HDAC3 knockdown was
combined with submaximal global HDAC inhibition. Persis-
tent activity of a large cellular pool of HDAC protein, despite
mRNA inhibition, could explain this finding. Alternatively, as
has been reported with other HDACs, HDAC3 may function
as a transcriptional repressor via a function that does not
depend on its deacetylase activity (7, 17, 28). In the presence of
global HDAC enzymatic inhibition, HDAC3 may continue to
restrict LTR expression. This repression could be relieved by
HDAC3 knockdown but would not be apparent without inhi-
bition of other resident HDACs, e.g., HDAC1 and HDAC2.
It has been demonstrated by five independent research
groups that HDAC1 is recruited to the LTR in cell line models
of HIV-1 latency by an array of transcription factors (Fig. 3B)
(4, 10, 12, 20, 23, 26). The existence of multiple mechanisms for
the recruitment of this HDAC implies that it plays a role in
maintaining LTR repression. Furthermore, in a chemical li-
brary screen of small-molecule HDAC inhibitors at Merck
Laboratories, a decreasing HDAC1 50% inhibitory concentra-
tion correlated with an increase of LTR activation in HeLa
P4/R5 cells (8). However, targeted HDAC1 inhibition by
siRNA did not substantially increase LTR expression (Fig.
4A). Thus, while HDAC1 may contribute to the maintenance
of deacetylated histones at the latent LTR, other HDACs
appear to compensate for the loss of HDAC1 when its expres-
sion is dampened.
Future efforts to evaluate the impact of targeted HDAC
knockdown on latent viral outgrowth from the resting CD4 T
cells of HIV-1-positive patients are warranted to verify the
importance of these findings for HIV-1 latency. Targeting a
combination of selected HDACs (e.g., HDAC2 and HDAC3
or HDAC1, -2, and -3) may prove to be a more effective
strategy for inducing HIV-1 expression in a broad population
of cells in vivo, as HDAC expression is cell and tissue type
specific (5). The discovery and development of new com-
pounds with selective HDAC-inhibitory abilities are an area of
intense research (reviewed in references 11 and 13). HDAC
inhibitors are currently in use in numerous clinical trials for
cancer treatment (6, 21), and the selective HDAC inhibitor
vorinostat has been approved for the treatment of subcutane-
ous T-cell lymphoma (19). We have recently shown that vori-
nostat can induce expression of HIV-1 from the resting CD4
T cells of HIV-1-infected patients (1). Thus, selective HDAC
inhibitors are viable candidates to explore as potential antila-
tency therapies.
Our results indicate that HDAC1, -2, and -3 are expressed in
the nuclei of the latent reservoir of resting CD4 T cells in
HIV-1-positive patients. HDAC1, -2, and -3 occupy the HIV-1
LTR in the J89GFP model of HIV-1 latency, and siRNA-
mediated knockdown of HDAC2 and HDAC3 can reactivate
the integrated, quiescent LTR of HeLa P4/R5 cells. These
observations suggest that the use of a class I selective HDAC
inhibitor, in particular one that acts on HDAC1, -2, and -3,
may prove to be an attractive antilatency strategy with fewer of
the toxicities that can accompany global HDAC inhibition.
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